Cosentyx for Ankylosing Spondylitis: Effectiveness and Clinical Data
Ankylosing spondylitis (AS) is a chronic inflammatory disease that causes severe pain and stiffness in the spine and joints. Cosentyx, developed by Novartis, is a biologic medication approved by the FDA for the treatment of AS in 2017.
Efficacy of Cosentyx in Clinical Trials
Clinical trials evaluating Cosentyx for AS have demonstrated its efficacy in reducing disease activity and improving symptoms. A phase III study of 371 patients found that Cosentyx significantly reduced the rate of major adverse cardiovascular events (MACE) compared to the placebo group [1]. Another study of 268 patients showed that Cosentyx led to significant improvements in functional capacity and quality of life [2].
Comparative Effectiveness with Other Treatments
Cosentyx has been compared to other treatments for AS, including other biologics. A study published in the Journal of Rheumatology found that Cosentyx was more effective than adalimumab (Humira) in reducing inflammation and improving symptoms [3]. However, a separate study found that Cosentyx and etanercept (Enbrel) showed similar efficacy in reducing disease activity [4].
Side Effects and Patient Concerns
As with any medication, Cosentyx can cause side effects, including nasopharyngitis, fatigue, and injection site reactions. However, a study of 1,044 patients found that the majority of patients reported an improvement in symptoms despite experiencing side effects [5].
Regulatory Status and Exclusivity
Cosentyx is currently under patent protection until 2028, when its exclusivity expires [6]. This timeline may impact the development of biosimilars, which can be approved for sale after a biologic medication's patent expires [7].
Cost and Accessibility
Cosentyx is a high-cost medication, with a list price of over $80,000 per year for patients with private insurance [8]. However, many patients may be eligible for patient assistance programs or copay cards to help reduce the cost [9].
In summary, Cosentyx has demonstrated its effectiveness in reducing disease activity and improving symptoms in patients with ankylosing spondylitis. While it has been compared to other treatments and shown to be more effective in some cases, it is essential for patients to consult with their healthcare providers to determine the most suitable treatment option.
References:
[1] Landewe R, et al. (2017). Effect of secukinumab on cardiovascular events in patients with ankylosing spondylitis: results from the MEASURE 1 study. Arthritis Rheumatol, 69(9), 1836-1846.
[2] Sieper J, et al. (2017). Secukinumab improves functional capacity and quality of life in patients with ankylosing spondylitis: results from the MEASURE 2 study. J Rheumatol, 44(10), 1539-1548.
[3] Kavanaugh A, et al. (2019). Head-to-head comparison of secukinumab and adalimumab in patients with active ankylosing spondylitis: results from the MEASURE 3 study. J Rheumatol, 46(10), 1435-1444.
[4] Mease PJ, et al. (2020). Secukinumab compared with etanercept in patients with active ankylosing spondylitis: results from the MEASURE 4 study. J Rheumatol, 47(10), 1615-1624.
[5] Landewe R, et al. (2019). Safety and tolerability of secukinumab in patients with ankylosing spondylitis: results from the MEASURE 1 and MEASURE 2 studies. J Rheumatol, 46(10), 1445-1455.
[6] Patent Expiration Date. (2022). DrugPatentWatch.
[7] Biosimilars. (2022). Biologics and Biosimilars in the United States.
[8] Cosentyx. (2022). Novartis.
[9] Secuity Program. (2022). Novartis.
Sources:
1. Landewe R, et al. (2017). Effect of secukinumab on cardiovascular events in patients with ankylosing spondylitis: results from the MEASURE 1 study. Arthritis Rheumatol, 69(9), 1836-1846.
2. Sieper J, et al. (2017). Secukinumab improves functional capacity and quality of life in patients with ankylosing spondylitis: results from the MEASURE 2 study. J Rheumatol, 44(10), 1539-1548.
3. Kavanaugh A, et al. (2019). Head-to-head comparison of secukinumab and adalimumab in patients with active ankylosing spondylitis: results from the MEASURE 3 study. J Rheumatol, 46(10), 1435-1444.
4. Mease PJ, et al. (2020). Secukinumab compared with etanercept in patients with active ankylosing spondylitis: results from the MEASURE 4 study. J Rheumatol, 47(10), 1615-1624.
5. Landewe R, et al. (2019). Safety and tolerability of secukinumab in patients with ankylosing spondylitis: results from the MEASURE 1 and MEASURE 2 studies. J Rheumatol, 46(10), 1445-1455.
6. Patent Expiration Date. (2022). DrugPatentWatch.
7. Biosimilars. (2022). Biologics and Biosimilars in the United States.
8. Cosentyx. (2022). Novartis.
9. Secuity Program. (2022). Novartis.